Can Stemness and Chemoresistance Be Therapeutically Targeted via Signaling Pathways in Ovarian Cancer?

por Roy, Lynn, Cowden Dahl, Karen D.
Publicado 2018

Age Is Just a Number: Considerations for Older Adults in Cancer Clinical Trials

por Habr, Dany, McRoy, Lynn, Papadimitrakopoulou, Vassiliki A
Publicado 2021

MiR-24 Is Required for Hematopoietic Differentiation of Mouse Embryonic Stem Cells

por Roy, Lynn, Bikorimana, Emmanuel, Lapid, Danica, Choi, Hyewon, Nguyen, Tan, Dahl, Richard
Publicado 2015

Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice

por Brufsky, Adam, Liu, Xianchen, Li, Benjamin, McRoy, Lynn, Layman, Rachel M.
Publicado 2021

Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis

por Brufsky, Adam, Liu, Xianchen, Li, Benjamin, McRoy, Lynn, Layman, Rachel M.
Publicado 2022

Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer

por Rugo, Hope S., Liu, Xianchen, Li, Benjamin, McRoy, Lynn, Layman, Rachel M., Brufsky, Adam
Publicado 2023

Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Exp...

por Maculaitis, Martine C, Liu, Xianchen, Will, Oliver, Hanson, Madelyn, McRoy, Lynn, Berk, Alexandra, Crastnopol, Melissa
Publicado 2020

Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer

por Rugo, Hope S, Liu, Xianchen, Li, Benjamin, McRoy, Lynn, Chen, Connie, Layman, Rachel M, Brufsky, Adam
Publicado 2023

Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older

por Brufsky, Adam, Liu, Xianchen, Li, Benjamin, McRoy, Lynn, Chen, Connie, Layman, Rachel M., Rugo, Hope S.
Publicado 2023

Palbociclib Combined with an Aromatase Inhibitor in Patients with Breast Cancer with Lung or Liver Metastases in US Clinical Practice

por Brufsky, Adam, Liu, Xianchen, Li, Benjamin, McRoy, Lynn, Chen, Connie, Layman, Rachel M., Rugo, Hope S.
Publicado 2023

ARID3B increases ovarian tumor burden and is associated with a cancer stem cell gene signature

por Roy, Lynn, Samyesudhas, Serene J., Carrasco, Martin, Li, Jun, Joseph, Stancy, Dahl, Richard, Dahl, Karen D. Cowden
Publicado 2014

CD133 Promotes Adhesion to the Ovarian Cancer Metastatic Niche

por Roy, Lynn, Bobbs, Alexander, Sattler, Rachel, Kurkewich, Jeffrey L, Dausinas, Paige B, Nallathamby, Prakash, Cowden Dahl, Karen D
Publicado 2018

Psychosocial Wellbeing among Patients with Breast Cancer during COVID-19

por Maculaitis, Martine C., Liu, Xianchen, Berk, Alexandra, Massa, Angelina, Weiss, Marisa C., Kurosky, Samantha K., Li, Benjamin, McRoy, Lynn
Publicado 2023

A prospective observational study of patient-reported functioning and quality of life in advanced and metastatic breast cancer utilizing a novel mobile application

por Richardson, David, Zhan, Lin, Mahtani, Reshma, McRoy, Lynn, Mitra, Debanjali, Reynolds, Maria, Odom, Dawn, Hollis, Kelly, Kaye, James A., Jones, Cheryl, Hargis, Jeffrey
Publicado 2021

Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice

por DeMichele, Angela, Cristofanilli, Massimo, Brufsky, Adam, Liu, Xianchen, Mardekian, Jack, McRoy, Lynn, Layman, Rachel M., Emir, Birol, Torres, Mylin A., Rugo, Hope S., Finn, Richard S.
Publicado 2021

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer

por Rugo, Hope S., Brufsky, Adam, Liu, Xianchen, Li, Benjamin, McRoy, Lynn, Chen, Connie, Layman, Rachel M., Cristofanilli, Massimo, Torres, Mylin A., Curigliano, Giuseppe, Finn, Richard S., DeMichele, Angela
Publicado 2022

Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer

por DeMichele, Angela, Robert, Nicholas, Chen, Connie, Kim, Sindy, Zhang, Zhe, Lu, Dongrui Ray, Aguilar, Kathleen M., Wang, Yunfei, Li, Benjamin, Schneeweiss, Sebastian, Rassen, Jeremy A., Gaffney, Michael, McRoy, Lynn
Publicado 2023

Prognostic Factors for Overall Survival in Patients with Hormone Receptor‐Positive Advanced Breast Cancer: Analyses From PALOMA‐3

por Rugo, Hope S., Cristofanilli, Massimo, Loibl, Sybille, Harbeck, Nadia, DeMichele, Angela, Iwata, Hiroji, Park, Yoon Hee, Brufsky, Adam, Theall, Kathy Puyana, Huang, Xin, McRoy, Lynn, Bananis, Eustratios, Turner, Nicholas C.
Publicado 2021

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast...

por Finn, Richard S., Boer, Katalin, Bondarenko, Igor, Patel, Ravindranath, Pinter, Tamas, Schmidt, Marcus, Shparyk, Yaroslav V., Thummala, Anu, Voitko, Nataliia, Bananis, Eustratios, McRoy, Lynn, Wilner, Keith, Huang, Xin, Kim, Sindy, Slamon, Dennis J., Ettl, Johannes
Publicado 2020